AI-Powered Analysis Shows Promising Liver Fibrosis Improvement with Zabopegdutide in Phase 2 Trial

HistoIndex and D&D Pharmatech announced positive results from the Phase 2 trial of zabopegdutide, an investigational treatment for metabolic dysfunction-associated steatohepatitis (MASH). AI-driven analysis demonstrated significant liver fibrosis improvement in treated patients, highlighting the drug’s potential benefits, including weight loss and better glycemic control. The trial’s findings were corroborated by an independent AI assessment confirming meaningful treatment-related improvements in fibrosis stages. These advancements underscore the efficacy of AI tools in the evaluation of liver disease therapies.